- ►shouxi.net A Vella, G Bock, PD Giesler, DB Burton, DB … - Diabetes, 2007 - Am Diabetes Assoc RESULTS— Fasting (7.3 ± 0.5 vs. 7.9 ± 0.5 mmol/l) and peak postprandial
(14.1 ± 0.6 vs. 15.9 ± 0.9 mmol/l) glucose concentrations were lower (P <
0.01) after vildagliptin treatment than placebo. Despite lower glucose ... Cited by 54 - Related articles - BL Direct - All 6 versions
- ►endojournals.org B Balas, MR Baig, C Watson, BE Dunning, M … - Journal of Clinical Endocrinology & Metabolism, 2007 - Endocrine Soc Results: After vildagliptin, suppression of endogenous glucose production (EGP)
during 6-h MTT was greater than with placebo (1.02 ± 0.06 vs. 0.74 ± 0.06
mg·kg –1 ·min –1 ; P = 0.004), and insulin secretion rate increased ... Cited by 66 - Related articles - BL Direct - All 5 versions
MN Rochester, N Pharmaceuticals, NJ East … - Am Diabetes Assoc Page 1. Vella A. et al. 1 Effects of Dipeptidyl Peptidase 4 Inhibition on
Gastrointestinal Function, Meal Appearance and Glucose Metabolism in Type 2 Diabetes ... Related articles
A Schweizer, A Couturier, JE Foley, S Dejager - Diabetic Medicine, 2007 - interscience.wiley.com It is also possible that your web browser is not configured or not able to
display style sheets. In this case, although the visual presentation will be
degraded, the site should continue to be functional. We recommend using the ... Cited by 89 - Related articles - BL Direct - All 4 versions
AJ Garber, A Schweizer, MA Baron, E … - Diabetes, Obesity and Metabolism, 2007 - interscience.wiley.com It is also possible that your web browser is not configured or not able to
display style sheets. In this case, although the visual presentation will be
degraded, the site should continue to be functional. We recommend using the ... Cited by 109 - Related articles - All 5 versions
YL He, Y Wang, JM Bullock, CF Deacon, JJ … - The Journal of Clinical Pharmacology, 2007 - jclinpharm.highwire.org This randomized, open-label, placebo-controlled, 7-period crossover study
assessed dose-response relationships following single oral doses (10-400 mg) of
vildagliptin in 16 patients with type 2 diabetes mellitus. Plasma levels of ... Cited by 31 - Related articles - BL Direct - All 6 versions
- ►adisonline.com [PDF] YL He, D Serra, Y Wang, J Campestrini, GJ … - Clinical pharmacokinetics, 2007 - ingentaconnect.com 1 Novartis Institutes for BioMedical Research, Inc., Cambridge, Massachusetts,
USA 2 Novartis Pharmaceutical Corporation, East Hanover, New Jersey, USA 3
Novartis Pharmaceuticals SAS, Rueil-Malmaison, France 4 Panum Institute, ... Cited by 25 - Related articles - BL Direct - All 5 versions
- ►endojournals.org K Azuma, Z Radikova, J Mancino, FGS Toledo, … - Journal of Clinical Endocrinology & Metabolism, 2008 - Endocrine Soc Objective: Pharmacological inhibition with the dipeptidyl peptidase 4 (DPP-4)
inhibitor vildagliptin prolongs the action of endogenously secreted incretin
hormones leading to improved glycemic control in patients with type 2 ... Cited by 24 - Related articles - BL Direct - All 4 versions
B Ahren, G Pacini, A Tura, JE Foley, A … - Hormone and metabolic research= Hormon-und …, 2007 - ncbi.nlm.nih.gov The aim of this study was to evaluate the contribution of insulin processing to
the improved meal-related B-cell function previously shown with the DPP-4
inhibitor vildagliptin. Fifty-five patients with type 2 diabetes ... Cited by 15 - Related articles - BL Direct - All 3 versions
S Dejager, S Razac, JE Foley, A Schweizer - Hormone and metabolic research, 2007 - cat.inist.fr This 24-week double-blind, randomized, multicenter, placebo-controlled,
parallel-group study was performed in 632 drug-naïve patients with type 2
diabetes to assess efficacy and tolerability of vildagliptin(50 mg qd, 50 ... Cited by 76 - Related articles - BL Direct - All 4 versions
